XBiotech appoints renowned immunologist Dr. Tak W. Mak to its Board of Directors

XBiotech Inc.

Dr. Mak appointed December 24, 2024 to fill board vacancy; will serve until next annual meeting.
Dr. Mak is a professor at University of Toronto, cloned T cell receptor (1984), and identified immune checkpoint CTLA-4.
He co-founded Agios Pharmaceuticals, which developed multiple FDA-approved cancer treatments.
Audit Committee remains two independent directors (McKenzie, Waldin); vacancy to be filled per Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.